Improving T-cell therapy with antigen specific T-cells
Targeted agents in acute myeloid leukemia in elderly patients
How molecular testing guides treatment in AML
Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)
Gerrit Jan Schuurhuis
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?